ONCAlert | Upfront Therapy for mRCC

Expanding on Data Surrounding Isatuximab Plus Pomalidomide/Dexamethasone in R/R Myeloma

Simon J. Harrison, MD
Published Online: 10:30 PM, Sun September 15, 2019

Simon J. Harrison, MD, director, Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.
 
The main purpose of the study was to analyze the data from studies of isatuximab with pomalidomide (Pomalyst), and dexamethasone in patients with relapsed or refractory (R/R) multiple myeloma who have cytogenetic abnormalities contributing to their higher risk level. The study showed that the benefit of the regimen was maintained in high-risk patients, even though patients with cytogenetic abnormalities have worse outcomes overall.    

The important factors to take away from the ICARIA-MM study are that high-risk patients with cytogenetic abnormalities have as much benefit as standard-risk patients. Therefore, oncologists should not hesitate to use this regimen in this patient population, Harrison suggests. It is also important to acknowledge that the high-risk patients have better responses to the isatuximab plus pomalidomide and dexamethasone combination than standard-risk patients with R/R multiple myeloma.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.